STOCK TITAN
  1. Home
  2. News
  3. FBIO

Fortress Biotech Inc - FBIO STOCK NEWS

Welcome to our dedicated news page for Fortress Biotech (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fortress Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fortress Biotech's position in the market.

News
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Rhea-AI Summary
Cyprium Therapeutics, a subsidiary of Fortress Biotech, receives a $4.1 million grant from NIH to advance AAV-ATP7A gene therapy in conjunction with CUTX-101 for Menkes disease treatment. The combination shows promising results in preclinical studies, aiming to be the first FDA-approved treatment for this rare pediatric disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
none
-
News
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Rhea-AI Summary
Journey Medical Corporation (DERM) submits NDA for DFD-29, a potential best-in-class oral medication for rosacea treatment, supported by positive Phase 3 clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
-
News
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Fortress Biotech, Inc. (FBIO) announced the closing of a registered direct offering, issuing 3,303,305 shares of common stock and warrants at a combined offering price of $3.33 per share, resulting in gross proceeds of approximately $11.0 million. The transaction closed on January 3, 2024, with Roth Capital Partners acting as the exclusive placement agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
offering
News
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a credit facility with SWK Holdings Corporation for up to $20 million to support general corporate purposes and potential launch of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
none
-
News
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) has entered into a definitive agreement for the issuance and sale of 3,303,305 shares of its common stock and warrants to purchase up to 3,303,305 shares of common stock at a combined offering price of $3.33 per share of common stock and accompanying warrant priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $11.0 million. Fortress expects to use the net proceeds from the offering for its operations, including, but not limited to, general corporate purposes, which may include research and development expenditures, clinical trial expenditures, license or acquisition of new products, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.62%
Tags
offering
-
News
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
Rhea-AI Summary
Sentynl Therapeutics, Inc. (Sentynl) has acquired worldwide proprietary rights and U.S. FDA documents for CUTX-101, a potential FDA-approved treatment for Menkes disease. The rolling submission of the New Drug Application to the FDA is ongoing and expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
News
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
Rhea-AI Summary
Cyprium Therapeutics, Inc. (Cyprium) received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones from Sentynl Therapeutics, Inc. (Sentynl) for the transfer of its proprietary rights and FDA documents pertaining to CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease. Cyprium will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101. The transfer aims to reduce Cyprium's development-related spend and potentially expedite commercialization upon FDA approval, with the drug demonstrating a compelling safety and efficacy profile for the treatment of Menkes disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
none
-
News
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) is on track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023. Positive topline data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea were reported in July 2023, achieving all co-primary and secondary endpoints with no significant safety issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
none
-
News
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced a 100% increase in total consolidated net revenue to $34.8 million in Q3 2023. The company is advancing late-stage clinical assets with potential NDA and BLA submissions to the FDA through 2024, including DFD-29 to treat rosacea. Recent corporate highlights include a $19 million upfront payment Journey Medical received for an exclusive license agreement with Maruho for commercialization of Qbrexza® in additional territories in Asia. Financial results show a decrease in consolidated cash, cash equivalents, and restricted cash to $74.7 million as of September 30, 2023, compared to $89.2 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
earnings
News
Fortress Biotech Announces Closing of $10.0 Million Public Offering
Rhea-AI Summary
Fortress Biotech, Inc. (Nasdaq: FBIO) announced the closing of a public offering, raising approximately $10.0 million in gross proceeds. The offering consisted of 5,885,000 units, each comprising one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $1.70 per unit. The net proceeds will be utilized for general corporate purposes, including research and development, clinical trials, product manufacture, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
offering
Stock FBIO logo
Fortress Biotech Inc

Nasdaq:FBIO

FBIO Rankings

#4921 Ranked by Market Cap
#5407 Ranked by Stock Gains
N/A Ranked by Dividends

FBIO Stock Data

34.62M
14.41M
26.31%
24.42%
9.79%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About FBIO

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.